RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+1.73%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$6.85B
AUM Growth
+$6.85B
(+3.3%)
Cap. Flow
+$642M
Cap. Flow
% of AUM
9.38%
Top 10 Holdings %
Top 10 Hldgs %
38.32%
Holding
136
New
16
Increased
27
Reduced
15
Closed
12
Top Buys
| 1 |
Ultragenyx Pharmaceutical
RARE
|
$115M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$94.1M |
| 3 |
Penumbra
PEN
|
$67.7M |
| 4 |
argenx
ARGX
|
$62M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
$52.9M |
Top Sells
| 1 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
$153M |
| 2 |
InMode
INMD
|
$19.9M |
| 3 |
IDEAYA Biosciences
IDYA
|
$17.6M |
| 4 |
Guardant Health
GH
|
$11.2M |
| 5 |
AGEN
Agenus
AGEN
|
$10.3M |
Sector Composition
| 1 | Healthcare | 93.33% |
| 2 | Financials | 0.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Outset Medical
OM
$245M
| $41.2M | 0.6% |
894,652
| – | – |
|
|
OYST
52
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
| $37.6M | 0.55% |
2,058,504
+197,295
| +11% | +$3.6M |
|
53
ESSA Pharma
EPIX
$11.2M
| $37.4M | 0.55% |
2,637,192
| – | – |
|
54
Pulmonx
LUNG
$67.6M
| $37.3M | 0.55% |
1,164,600
| – | – |
|
55
Ventyx Biosciences
VTYX
$184M
| $30.8M | 0.45% |
+1,551,778
| New | +$30.8M |
|
56
Quanterix
QTRX
$202M
| $29.1M | 0.43% |
+686,470
| New | +$29.1M |
|
57
Milestone Pharmaceuticals
MIST
$151M
| $28.3M | 0.41% |
4,315,102
| – | – |
|
58
CytomX Therapeutics
CTMX
$350M
| $26.1M | 0.38% |
6,029,700
+4,628,761
| +330% | +$20M |
|
59
Castle Biosciences
CSTL
$673M
| $25.7M | 0.38% |
599,009
| – | – |
|
|
NSTG
60
DELISTED
NanoString Technologies, Inc.
NSTG
| $25.5M | 0.37% |
604,029
-200,000
| -25% | -$8.45M |
|
61
Athira Pharma
ATHA
$15.5M
| $24.8M | 0.36% |
1,906,557
| – | – |
|
62
Monte Rosa Therapeutics
GLUE
$309M
| $24.8M | 0.36% |
1,214,572
| – | – |
|
|
JNCE
63
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $23.9M | 0.35% |
2,863,198
+1,466,995
| +105% | +$12.2M |
|
64
Pyxis Oncology
PYXS
$91.2M
| $23.3M | 0.34% |
+2,120,760
| New | +$23.3M |
|
65
Arrowhead Research
ARWR
$3.84B
| $23M | 0.34% |
+346,842
| New | +$23M |
|
|
CERE
66
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $21.6M | 0.32% |
666,666
| – | – |
|
67
Johnson & Johnson
JNJ
$429B
| $21.4M | 0.31% |
125,127
-45,415
| -27% | -$7.77M |
|
68
Sight Sciences
SGHT
$199M
| $20.8M | 0.3% |
1,183,871
-100,000
| -8% | -$1.76M |
|
|
LABP
69
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
| $20.5M | 0.3% |
4,275,722
| – | – |
|
|
RCOR
70
DELISTED
Renovacor, Inc.
RCOR
| $20.4M | 0.3% |
2,647,540
+460,000
| +21% | +$3.54M |
|
|
AGEN
71
Agenus
AGEN
$136M
| $18.9M | 0.28% |
5,868,315
-3,206,123
| -35% | -$10.3M |
|
|
OLK
72
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
| $18.5M | 0.27% |
1,018,188
-300,000
| -23% | -$5.46M |
|
|
WHWK
73
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$85.3M
| $18.5M | 0.27% |
764,701
| – | – |
|
74
TELA Bio
TELA
$65.4M
| $17.9M | 0.26% |
1,399,686
+8,067
| +0.6% | +$103K |
|
75
Immunic
IMUX
$79.4M
| $16.4M | 0.24% |
1,715,470
+344,656
| +25% | +$3.3M |
|